reports
- Benoit Valleaux
- Steven Gould
- Research Department
INFORME DIARIO 17 OCTUBRE + RDOS. ESPAÑA Y EUROPA 3T’25. PREVIEWS (ANÁ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CELLNEX, FERROVIAL, IBERDROLA. EUROPA: ESSILORLUXOTTICA, INTESA SANPAOLO, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. El gobierno de Lecornu sobrevive por ahora Ganancias en las bolsas europeas, que se beneficiaron del menor rie...
- Ahmed Ben Salem
- Baptiste Lebacq
TEMN TEMENOS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
HCO HIGHCO SA
GLO GL EVENTS SA
ENI ENI S.P.A.
BAMNB KONINKLIJKE BAM GROEP NV
REP REPSOL SA
SIX2 SIXT SE
SLIGR SLIGRO FOOD GROUP N.V.
FDR FLUIDRA S.A.
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BP. BP P.L.C.
PWG PRODWAYS GROUP SA
THEP THERMADOR HOLDING SA
FAST FASTNED
ALHRS HYDROGEN REFUELING SOLUTIONS
SHEL SHELL PLC
CAN CANAL+
- Ahmed Ben Salem
- Baptiste Lebacq
TEMN TEMENOS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
HCO HIGHCO SA
GLO GL EVENTS SA
ENI ENI S.P.A.
BAMNB KONINKLIJKE BAM GROEP NV
REP REPSOL SA
SIX2 SIXT SE
SLIGR SLIGRO FOOD GROUP N.V.
FDR FLUIDRA S.A.
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BP. BP P.L.C.
PWG PRODWAYS GROUP SA
THEP THERMADOR HOLDING SA
FAST FASTNED
ALHRS HYDROGEN REFUELING SOLUTIONS
SHEL SHELL PLC
CAN CANAL+
- Martijn Den Drijver
- Research Department
INFORME DIARIO 15 OCTUBRE + RDOS. EUROPA 3T’25. PREVIEWS (ANÁLISIS BAN...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENAGÁS, INMOBILIARIA COLONIAL, VISCOFAN. EUROPA: ASML, INTESA SANPAOLO, LVMH, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. De nuevo, el frente comercial Correcciones en los índices de Europa, enfrascados en el enfrentamiento come...
- Research Department
INFORME DIARIO 08 OCTUBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: SANTANDER, SECTOR ACERO. EUROPA: BMW, INTESA SAN PAOLO, UNICREDIT. Francia se mantiene en una sesión de ventas Con la mayoría de los índices europeos a la baja, sorprendió la estabilidad del CAC francés a pesar de que no se atisban soluciones a la paralización política de Francia. Mientras, EE.UU. se vio lastrado por otro nuevo día de shutdown y la noticia de Oracle de deterioro de márgenes en centros de datos con chips de Nvidia. En el STOXX 600 l...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in particip...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Res...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p
Intesa Sanpaolo S.p.A.: 1 director
A director at Intesa Sanpaolo S.p.A. sold 60,000 shares at 5.676EUR and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Abivax Announces Acceptance of Additional Late-Breaking Abstract from ...
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) ...
- Fehmi Ben Naamane
- Fehmi Ben Naamane
- Javier Esteban
- Andreas Riemann
- Research Department
INFORME DIARIO 26 SEPTIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, INDRA, SECTOR BANCARIO, SECTOR FARMA. EUROPA: INTESA SAN PAOLO, UNICREDIT. Las bajadas de tipos pierden fuerza Caídas en las bolsas europeas, ya que la fortaleza en los datos de empleo americanos y los últimos comentarios desde la Fed enfrían las probabilidades de ver las bajadas de tipos que el mercado espera (futuros de los fed funds a dic’25 corrigen al alza hasta el 3,76%). Así, en el STOXX 600 los mejores sectores fueron R. Básicos y Ret...
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod...
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax manage...
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.